Recently, with  a total investment of RMB 3 billion, Henry – hansoh  new medicine industry park start the construction in Lingang Industrial Park of  jiangsu Lianyungang ETDZ. Phase I investment of the project is RMB 1.2 billion, covering an area of 105,000 square meters. The whole project will be completed within 5 years. After completion, RMB 10 billion of annual sales, RMB 2 billion taxes can be achieved. Its preparation products will enter the international market, and U.S $ 200 million exports can be achieved.

to further enlarge and strengthen the enterprise, as well as to meet the requirements of the production of a new category products and expanding its international and domestic market, Henry pharmaceutical Co. and HANSOH pharmaceutical Co. joint together to invest the Henry- Hansoh new medicine industrial Park. Preparation plant and office buildings, research institute, public works and ancillary facilities are built in line with the international-class standards such as U.S. FDA, the European Union EPDM. Henry – Hansoh new medicine industrial Park will build workshops to produce solid anti-tumor and normal preparations, freeze-dried and squired cut , infusion agents, contrast dye, biological and protein productions, mainly focus on the production of over 10 kinds of medicines, such as  Imatinib Mesylate, Imrecoxib, and Lapatini etc., covering the fields of anti-tumor, gastrointestinal, antibiotics, cardiovascular and cerebrovascular diseases. In the next 5 years, Henry medicine, and hansoh Pharmaceutical Group will have 5 to 6 innovative medicines with independent intellectual property rights to for sale.